CentoCancer™ – CENTOGENE's cancer-risk-related panel, for all patients with a positive family history of cancer
The correct profiling of mutations in cancer genes represents a fundamental step in the diagnosis and treatment of these malignancies. Certain mutations result in increased risk of hereditary cancer, and lead to development of different types of cancer.
Achieve the best possible approach for your patient
CENTOGENE now offers CentoCancer™ – a specific and sensitive panel with highly penetrant cancer genes. With this panel we would like to offer you a complete answer to achieve the best possible therapeutic approach for your patients.
Each gene in CentoCancer™ has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer.
Who should consider CentoCancer™ for genetic testing?
- Affected individuals with an increased risk of hereditary cancer indicated by family history, multifocal tumor development or early onset
- Non-affected individuals with a positive family history
CentoCancer™ addresses people with an identified cancer where the type of cancer or the family history warrant an extended NGS panel analysis, or those who have no family history, no positive anamnesis and would like to know their risk of inherited cancer.
Scientific Articles on Hereditary Cancer
In this webinar you will learn the last insights in oncogenetics testing and how CENTOGENE gene panels can support you to assess the risk of a patient to develop an inherited cancer.
Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer
We explored a more efficient genetic screening strategy based on next-generation sequencing of the BRCA1 and BRCA2 genes in 210 hereditary breast and/or ovarian cancer patients.
Strive for the most complete information
CENTOGENE's CentoCancer™ is a 31-gene panel that identifies an elevated risk of significant hereditary cancers, including breast, ovarian, gastric, colon, endometrial, prostate, pancreatic, renal, liver and skin cancer.
CentoCancer™ includes the most relevant genes: APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NBN, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11 and TP53.
NGS bidirectional sequencing is used for all genes in the panel, including 100% coding region (all exons), exon/intron boundaries +/-10bp, with validation for every genetic variant detected.